" class="no-js "lang="en-US"> Obsidian Therapeutics - Medtech Alert
Friday, March 29, 2024
Obsidian Therapeutics | Pharmtech Focus

Obsidian Therapeutics

About Obsidian Therapeutics

Obsidian Therapeutics

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients.

Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need.

Located in the heart of Cambridge, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.

Related Story

Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments

May 24 2023

Obsidian Therapeutics, a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the […]

MD Anderson and Obsidian Therapeutics Announce FDA Clearance of IND Application for Novel TIL Therapy Obx-115

July 25 2022

The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA) clearance […]

Obsidian Therapeutics Appoints Lee Giguere, J.D., as Chief Legal Officer and Corporate Secretary

December 8 2021

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced the […]

Obsidian Therapeutics Appoints Maria Fardis, Ph.D., to Board of Directors

October 22 2021

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced the […]